Penile Traction Therapy Results & Expected Outcomes

Clinical studies consistently demonstrate that penile traction therapy produces measurable, statistically significant improvements in penile length when patients adhere to standardized treatment protocols. Across more than fifteen peer-reviewed clinical studies involving over 1,000 patients, researchers have documented average length gains ranging from 1.3 to 2.3 cm (0.5 to 0.9 inches) over treatment periods of three to six months. These expected outcomes are not marketing projections — they represent objective clinical results measured under controlled conditions using standardized protocols for stretched penile length and erect penile length.

Penile traction therapy that actually works does so through mechanotransduction — the cellular response to sustained mechanical force — which triggers permanent tissue expansion and collagen remodeling. The SizeGenetics device, an FDA-registered Class II medical device manufactured by Danamedic ApS in Denmark since 1994, delivers calibrated tension between 900–2,800 grams (8.8–27.5 Newtons) to achieve these validated clinical outcomes.

Clinical Outcomes

Objective, quantifiable gains in penile length and girth measured by clinicians using standardized protocols. The 2023 systematic review and meta-analysis by Almsaoud, Safar, and Alshahrani confirmed a weighted mean length gain of 1.9 cm across twelve pooled studies.

Treatment Response

The degree of measured improvement varies between individuals based on adherence rate, baseline anatomy, tension levels, and duration of therapy. Compliant patients — those maintaining 4–6 hours of daily use — achieve the highest quantifiable gains.

Individual Variation

Responders and non-responders exist within every clinical trial population. Factors including age, tissue elasticity, consistency of use, and baseline measurements influence where each patient falls on the therapeutic effects spectrum.

Multiple clinical studies report consistent, measurable penile length gains from traction therapy across diverse patient populations, study designs, and treatment durations. The following table summarizes objective results from the most rigorous peer-reviewed research, including randomized controlled trials, prospective cohort studies, and the definitive 2023 meta-analysis.

The clinical investigation of penile traction therapy results spans three decades, beginning with the pioneering device developed by Dr. Jørn Ege Siana, plastic surgeon and co-inventor of the first penile traction device, at Danamedic ApS in 1994. Gontero and colleagues, publishing in the Journal of Sexual Medicine (2009), documented a mean gain of 1.3 cm in their prospective cohort of 15 patients who used a penile traction device for 4–6 hours daily over six months. Nikoobakht and colleagues (2010) reported gains of 1.7 cm in both flaccid and stretched penile length in a cohort of 23 men — increasing flaccid length from 8.8 cm to 10.5 cm and stretched length from 11.5 cm to 13.2 cm. For the full clinical evidence base, see our comprehensive study analysis.

The strongest evidence comes from the two largest randomized controlled trials. Joseph and colleagues (2020) enrolled 110 participants and reported that 94% achieved increased length, with mean gains between 1.6 and 2.3 cm depending on adherence. Toussi and colleagues, publishing in the Journal of Urology (2021), demonstrated that penile traction therapy produced a statistically significant gain of 1.6 cm compared to just 0.3 cm in the control group (p<0.01) among 82 men following prostatectomy.

Results from penile traction therapy develop progressively over weeks and months, following a predictable pattern of cumulative effects documented across clinical studies. Unlike pharmaceutical interventions that produce immediate but temporary changes, traction therapy produces gradual, permanent tissue expansion through sustained mechanotransduction. Understanding this treatment timeline helps patients set realistic milestone markers and maintain the consistency required for optimal treatment response.

• Consistency matters most: Daily use of 4–6 hours produces superior outcomes compared to sporadic, longer sessions
• Gradual tension progression: Starting at 900 grams and increasing to 2,800 grams as tissue adapts optimizes both safety and efficacy
• Measurement discipline: Standardized baseline measurements using stretched penile length allow objective tracking of therapy progression
• Patience is clinical: Tissue expansion through mechanotransduction requires sustained biological processes — weeks, not days

Individual results vary based on multiple physiological and behavioral factors that influence how effectively penile traction therapy produces measurable improvement. Clinical data shows that treatment adherence is the single strongest predictor of therapeutic outcomes — patients who maintain greater than 75% compliance consistently achieve substantially better results than those with inconsistent use patterns, as demonstrated across multiple clinical trials including the Almsaoud meta-analysis which documented an 82% mean adherence rate in successful studies.

Treatment Adherence

Compliance with the daily 4–6 hour wearing protocol correlates most strongly with clinical outcomes. The 2023 meta-analysis by Almsaoud and colleagues documented an 82% adherence rate across twelve pooled studies. Patients who consistently meet or exceed the recommended daily wear time achieve results at the upper end of the 1.3–2.3 cm range. The SizeGenetics 58-way Multi-Axis Comfort Technology directly impacts adherence by reducing discomfort during extended wear.

Baseline Anatomy

Starting penile length, tissue elasticity, and tunica albuginea thickness affect the rate and magnitude of treatment response. Treatment-naive patients — those who have not previously used traction devices — typically demonstrate stronger initial gains as tissue responds to the novel mechanical stimulus for the first time.

Age Factors

Younger patients generally exhibit faster cellular proliferation and collagen remodeling, though clinical studies have demonstrated meaningful gains across all adult age groups. Toussi and colleagues documented significant results in post-prostatectomy patients with a mean age of 58.6 years, confirming that age does not preclude effective treatment response.

Tension Calibration

Progressive tension adjustment from 900 to 2,800 grams (8.8 to 27.5 Newtons) as tissue adapts determines the magnitude of mechanotransduction response. Insufficient tension produces minimal cellular signaling; excessive tension risks the mild, temporary adverse events reported at rates of 11.2–14.4% across clinical studies — see safety considerations for full adverse event data.

Treatment Duration

The 3–6 month treatment window represents the standard clinical protocol, though individual response patterns vary. Some patients may require extended duration to achieve target outcomes, while others reach measurable improvement within the first three months, as Nikoobakht and colleagues documented.

Medical History

Pre-existing conditions including Peyronie's disease, post-surgical rehabilitation needs, and erectile dysfunction affect both the goals and the trajectory of treatment. Patients undergoing penile traction therapy for post-prostatectomy rehabilitation, as studied by Toussi and colleagues, demonstrate that the therapy benefits distinct clinical populations with different baseline characteristics.

Clinical data shows that the vast majority of compliant patients achieve clinically significant results from penile traction therapy, though response patterns vary across patient populations. Across the published evidence base — including the Joseph RCT where 94% of 110 participants achieved measurable gains, and the Toussi RCT showing statistically significant improvement over controls — the aggregate data indicates that approximately 70–80% of adherent patients demonstrate meaningful objective improvement in penile length measurements.

The Joseph randomized controlled trial provides the strongest success rate evidence: 94% of 110 participants achieved increased penile length. This exceptional response rate reflects the controlled conditions and structured adherence support within the clinical trial environment. Clinical before and after measurements — not patient self-report — confirmed these gains using standardized stretched penile length protocols. Toussi and colleagues reported that 87% of 82 men would choose to repeat penile traction therapy and 93% would recommend the treatment to others — demonstrating both efficacy and patient satisfaction with this FDA-registered medical device.

• Adherence predicts success: Patients maintaining >75% of prescribed daily wear time benefit most from penile traction therapy
• Time-dependent response: Patients who complete the full 3–6 month protocol demonstrate significantly better outcomes than those who discontinue early
• Objective measurement confirms results: Gains are measured using standardized protocols for stretched penile length and erect penile length — not patient self-report alone
• Population-validated results: Success rates remain consistent across clinical populations including post-surgical rehabilitation and Peyronie's disease patients — see penile lengthening outcomes for detailed length-specific data

Setting realistic expectations requires separating clinical evidence from the exaggerated claims that dominate the male enhancement industry. Penile traction therapy is the only non-surgical method validated by peer-reviewed clinical studies, but understanding exactly what the evidence supports — and what it does not — protects patients from disappointment and ensures informed treatment decisions.

Evidence-based outcomes from penile traction therapy are modest but real. The SizeGenetics device, backed by Danamedic's 30+ years of clinical research and manufacturing expertise, delivers results within the range validated by peer-reviewed evidence — not the inflated promises of unregulated supplements. Patients who approach penile traction therapy as a medical treatment with evidence-based expectations, rather than a miracle solution, achieve the highest satisfaction rates, as Toussi and colleagues confirmed with 87% willing to repeat therapy.

Long-term follow-up studies indicate that results from penile traction therapy are durable when patients follow appropriate maintenance protocols after completing the primary treatment phase. Gontero and colleagues documented that participants maintained their gains with no further change in penile length in the six months following device cessation, suggesting that the tissue expansion produced by sustained mechanotransduction creates permanent structural changes in the tunica albuginea and surrounding connective tissue.

The biological basis for result durability lies in the mechanism of action itself. Penile traction therapy triggers the reorganization and remodelling of collagen fibres into uniform densely packed fibrils parallel to the axis of mechanical strain, as Chung and Brock demonstrated in their 2013 review published in Translational Andrology and Urology. This collagen remodeling represents a permanent structural adaptation — not a temporary stretching effect that reverses when the device is removed.

• Primary treatment phase (3–6 months): Daily wear of 4–6 hours at progressive tension levels produces the majority of cumulative effects and measured improvement
• Maintenance phase (ongoing): Reduced wearing schedules of 2–3 sessions per week help sustain and preserve therapeutic gains long-term
• Follow-up monitoring: Periodic clinical evaluation using standardized measurement protocols confirms that gains stabilize and continue post-treatment
• Result retention: Follow-up data from the Gontero study showed stable maintenance of gains in the six months following device cessation, and clinical observation suggests the majority of initial gains are retained long-term when maintenance therapy is followed

SizeGenetics includes a 6-month money-back guarantee, covering the entire primary treatment duration recommended by clinical protocols. This guarantee reflects Danamedic's confidence in the evidence-based outcomes documented across three decades of clinical research — results delivered by an FDA-registered Class II medical device, not unvalidated consumer products.

Penile traction therapy results depend on understanding the broader clinical context — from the evidence base that validates these outcomes to the safety profile that makes long-term use viable and the treatment protocols that optimize individual response.

For device-specific clinical validation, see SizeGenetics Results & Clinical Validation. Patients managing Peyronie's disease can review condition-specific outcome data at curvature correction outcomes. Real-world experiences from verified users are collected at Patient Success Stories & Testimonials.